CMS (00867) Obtains NMPA Approval for Clinical Trials of INHBE-Targeting Drug CMS-D008 for Overweight/Obesity

Bulletin Express

Mar 04

China Medical System Holdings Limited (CMS, 00867) announced that on 4 March 2026, its self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection received approval from the National Medical Products Administration for clinical trials in overweight or obese individuals.

CMS-D008, administered by subcutaneous injection, targets and reduces the hepatic expression of the INHBE gene, lowering the level of Activin E protein. Preclinical studies indicated that CMS-D008 efficiently and sustainably suppressed INHBE expression, effectively reducing fat mass while retaining lean muscle in diet-induced obesity models. According to the announcement, this mechanism differs from that of GLP-1RAs, potentially providing prospects for high-quality, long-term weight management with a favorable safety profile.

The announcement cited global data projecting overweight and obesity to affect 3.00 billion adults worldwide, while the number of overweight or obese adults in China is projected to reach 515.00 million by 2030. CMS-D008 will be developed for overweight/obesity and related metabolic conditions, with potential synergy alongside the company’s GLP-1R/GCGR dual agonist CMS-D005. The goal is to drive effective and sustainable weight loss outcomes, leveraging CMS’s existing cardiovascular and metabolic networks to accelerate R&D and future commercialization of these products.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1112950092"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1112950092\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1112950092?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 19:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112950092","market":"hk","top_or_hot":-1,"title":"CMS (00867) Obtains NMPA Approval for Clinical Trials of INHBE-Targeting Drug CMS-D008 for Overweight/Obesity","media":"Bulletin Express","content":"<p>China Medical System Holdings Limited (CMS, 00867) announced that on 4 March 2026, its self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection received approval from the National Medical Products Administration for clinical trials in overweight or obese individuals.</p>\n<p>CMS-D008, administered by subcutaneous injection, targets and reduces the hepatic expression of the INHBE gene, lowering the level of Activin E protein. Preclinical studies indicated that CMS-D008 efficiently and sustainably suppressed INHBE expression, effectively reducing fat mass while retaining lean muscle in diet-induced obesity models. According to the announcement, this mechanism differs from that of GLP-1RAs, potentially providing prospects for high-quality, long-term weight management with a favorable safety profile.</p>\n<p>The announcement cited global data projecting overweight and obesity to affect 3.00 billion adults worldwide, while the number of overweight or obese adults in China is projected to reach 515.00 million by 2030. CMS-D008 will be developed for overweight/obesity and related metabolic conditions, with potential synergy alongside the company’s GLP-1R/GCGR dual agonist CMS-D005. The goal is to drive effective and sustainable weight loss outcomes, leveraging CMS’s existing cardiovascular and metabolic networks to accelerate R&D and future commercialization of these products.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CMS (00867) Obtains NMPA Approval for Clinical Trials of INHBE-Targeting Drug CMS-D008 for Overweight/Obesity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCMS (00867) Obtains NMPA Approval for Clinical Trials of INHBE-Targeting Drug CMS-D008 for Overweight/Obesity\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-04 19:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Medical System Holdings Limited (CMS, 00867) announced that on 4 March 2026, its self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection received approval from the National Medical Products Administration for clinical trials in overweight or obese individuals.</p>\n<p>CMS-D008, administered by subcutaneous injection, targets and reduces the hepatic expression of the INHBE gene, lowering the level of Activin E protein. Preclinical studies indicated that CMS-D008 efficiently and sustainably suppressed INHBE expression, effectively reducing fat mass while retaining lean muscle in diet-induced obesity models. According to the announcement, this mechanism differs from that of GLP-1RAs, potentially providing prospects for high-quality, long-term weight management with a favorable safety profile.</p>\n<p>The announcement cited global data projecting overweight and obesity to affect 3.00 billion adults worldwide, while the number of overweight or obese adults in China is projected to reach 515.00 million by 2030. CMS-D008 will be developed for overweight/obesity and related metabolic conditions, with potential synergy alongside the company’s GLP-1R/GCGR dual agonist CMS-D005. The goal is to drive effective and sustainable weight loss outcomes, leveraging CMS’s existing cardiovascular and metabolic networks to accelerate R&D and future commercialization of these products.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00867","symbol_name":"康哲药业","start_time":0,"source_url":"","article_id":"1112950092","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112950092","pubTimestamp":1772622362,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China Medical System Holdings Limited (CMS, 00867) announced that on 4 March 2026, its self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection received approval from...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00867":"康哲药业"},"translate_title":"康哲药业(00867)INHBE靶向药物CMS-D008治疗跑赢大盘病/肥胖症获NMPA批准临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00867":1},"content_text":"China Medical System Holdings Limited (CMS, 00867) announced that on 4 March 2026, its self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection received approval from the National Medical Products Administration for clinical trials in overweight or obese individuals.\nCMS-D008, administered by subcutaneous injection, targets and reduces the hepatic expression of the INHBE gene, lowering the level of Activin E protein. Preclinical studies indicated that CMS-D008 efficiently and sustainably suppressed INHBE expression, effectively reducing fat mass while retaining lean muscle in diet-induced obesity models. According to the announcement, this mechanism differs from that of GLP-1RAs, potentially providing prospects for high-quality, long-term weight management with a favorable safety profile.\nThe announcement cited global data projecting overweight and obesity to affect 3.00 billion adults worldwide, while the number of overweight or obese adults in China is projected to reach 515.00 million by 2030. CMS-D008 will be developed for overweight/obesity and related metabolic conditions, with potential synergy alongside the company’s GLP-1R/GCGR dual agonist CMS-D005. The goal is to drive effective and sustainable weight loss outcomes, leveraging CMS’s existing cardiovascular and metabolic networks to accelerate R&D and future commercialization of these products.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}